fetal demise
Recently Published Documents


TOTAL DOCUMENTS

619
(FIVE YEARS 188)

H-INDEX

31
(FIVE YEARS 6)

2022 ◽  
Vol 27 ◽  
pp. 300586
Author(s):  
Daniel S. Atherton ◽  
Brandi C. McCleskey ◽  
Virginia E. Duncan

Author(s):  
Reema Khajuria ◽  
Arushi Suri ◽  
Rohini Jaggi

Background: Misoprostol use in early pregnancy failure is varied and dose is not well established. Aim of this study was to compare efficacy and side effects of 600 versus 800 micrograms vaginal misoprostol in early pregnancy failure.Methods: A randomized prospective observational study was conducted in the postgraduate department of obstetrics and gynaecology, SMGS hospital Jammu from November 2018 to October 2019 after getting approval from the ethical committee. Hundred patients (50 in group A and 50 in group B) admitted in labour room before 12 weeks of gestation with an ultrasound diagnosis of early fetal demise (missed abortion or brightened ovum) were treated medically with different doses of vaginal misoprostol.Results: The success rate in patients in group A is 72% and group B is 88%, p=0.045 (difference is statistically significant). Patients who required suction and evacuation were 28% in group A and 12% in group B.Conclusions: Use of misoprostol for medical management of 1st trimester missed/anembryonic is an effective, cheap, safe and convenient alternative to surgical evacuation. It was concluded that 800 micrograms vaginal misoprostol is more effective than 600 micrograms vaginal misoprostol. But 800 micrograms misoprostol has more side effects than 600 micrograms vaginal misoprostol.


2022 ◽  
Vol 226 (1) ◽  
pp. S51
Author(s):  
Hiba J. Mustafa ◽  
Ali Javinani ◽  
Christopher Harman ◽  
Eyal Krispin ◽  
Alireza A. Shamshirsaz ◽  
...  
Keyword(s):  

2022 ◽  
Vol 226 (1) ◽  
pp. S172-S173
Author(s):  
Ahmed A. Nassr ◽  
Kamran Hessami ◽  
Jimmy Espinoza ◽  
Roopali V. Donepudi ◽  
Magdalena Sanz Cortes ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S285-S286
Author(s):  
Hiba J. Mustafa ◽  
Ali Javinani ◽  
Katherine Goetzinger ◽  
Faezeh Aghajani ◽  
Eyal Krispin ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S53
Author(s):  
Juliana S. Gebb ◽  
Rosa Hwang ◽  
Christina Paidas Teefey ◽  
Shelly Soni ◽  
Deborah M. Zarnow ◽  
...  

Cureus ◽  
2021 ◽  
Author(s):  
Dominic J Bewley ◽  
Jessica Lee ◽  
Oana Popescu ◽  
Angelica Oviedo

Viruses ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2545
Author(s):  
Pavel Babal ◽  
Lucia Krivosikova ◽  
Lucia Sarvaicova ◽  
Ivan Deckov ◽  
Tomas Szemes ◽  
...  

Background: SARS-CoV-2 infection in pregnant women can lead to placental damage and transplacental infection transfer, and intrauterine fetal demise is an unpredictable event. Case study: A 32-year-old patient in her 38th week of pregnancy reported loss of fetal movements. She overcame mild COVID-19 with positive PCR test 22 days before. A histology of the placenta showed deposition of intervillous fibrinoid, lympho-histiocytic infiltration, scant neutrophils, clumping of villi, and extant infarctions. Immunohistochemistry identified focal SARS-CoV-2 nucleocapsid and spike protein in the syncytiotrophoblast and isolated in situ hybridization of the virus’ RNA. Low ACE2 and TMPRSS2 contrasted with strong basigin/CD147 and PDL-1 positivity in the trophoblast. An autopsy of the fetus showed no morphological abnormalities except for lung interstitial infiltrate, with prevalent CD8-positive T-lymphocytes and B-lymphocytes. Immunohistochemistry and in situ hybridization proved the presence of countless dispersed SARS-CoV-2-infected epithelial and endothelial cells in the lung tissue. The potential virus-receptor protein ACE2, TMPRSS2, and CD147 expression was too low to be detected. Conclusion: Over three weeks’ persistence of trophoblast viral infection lead to extensive intervillous fibrinoid depositions and placental infarctions. High CD147 expression might serve as the dominant receptor for the virus, and PDL-1 could limit maternal immunity in placental tissue virus clearance. The presented case indicates that the SARS-CoV-2 infection-induced changes in the placenta lead to ischemia and consecutive demise of the fetus. The infection of the fetus was without significant impact on its death. This rare complication of pregnancy can appear independently to the severity of COVID-19’s clinical course in the pregnant mother.


2021 ◽  
pp. 491-493
Author(s):  
Nalini Sharma ◽  
Vinayak Jante ◽  
Rituparna Das ◽  
Subrat Panda ◽  
Mandeep Sagar

Hydranencephaly (HE) is a rare condition occurring in <1/10,000 births worldwide. It is one of the recognized forms of brain malformations that are usually associated with intrauterine fetal demise rarely seen in postnatal life. HE can often be misdiagnosed due to certain common features with other neurological abnormalities such as hydrocephalus, holoprosencephaly, and porencephaly. Here, we report the case of a 26-year-old pregnant patient at 34 weeks who was referred with ultrasonography finding of HE which was confirmed by fetal MRI. The decision to deliver the baby was taken expecting an extremely poor outcome after discussing with the family.


2021 ◽  
Vol 1 ◽  
Author(s):  
Dakshnapriya Balasubbramanian ◽  
Sathish Dharani ◽  
Mohammad Tauseef ◽  
Mansoor A. Khan ◽  
Ziyaur Rahman ◽  
...  

The maternal innate immune system plays a central role in preeclampsia (PE). Toll-like receptors (TLRs) are innate immune system receptors that recognize characteristics of extracellular endogenous ligands or pathogens, and their activation leads to a pro-inflammatory immune response. We and others have reported that excessive activation of TLRs causes pregnancy-dependent hypertension in animals and is associated with PE in women. Activation of TLR3 by poly I:C mimics the innate immune system activation by viruses that women who develop PE encounter during pregnancy. Vardenafil was approved by the FDA for erectile dysfunction but has recently been examined as a potential PE medication due to studies done with a similar drug, sildenafil. Preclinical as well as recent clinical studies demonstrate the potential effectiveness of sildenafil for PE. However, vardenafil is more potent than sildenafil and acts by increasing expression of placental growth factor in addition to increasing cGMP levels. We hypothesized that vardenafil will be more potent and effective in reducing the negative health effects in a mouse model of virus-induced PE. Pregnant mice were injected with the TLR3 agonist poly I:C (PPIC) on gestational days 13, 15, and 17. We treated PPIC mice with a high dose of vardenafil (50 mg human equivalent), a lower dose of vardenafil (20 mg human equivalent), or sildenafil (50 mg human equivalent) on gestational days 15–17 after hypertension was established. Daily i.p. injections of either high dose or low dose vardenafil significantly decreased systolic blood pressure in PPIC mice whereas sildenafil had no effect. There were no differences in body weight between the groups. The splenomegaly induced in PPIC mice was ameliorated in high dose vardenafil-treated PPIC mice, while low dose vardenafil-treated and sildenafil-treated PPIC mice still exhibited splenomegaly. High dose vardenafil-treated PPIC mice also did not exhibit any fetal demise characteristic of PPIC mice, while low dose vardenafil-treated and sildenafil-treated PPIC mice still had significantly increased incidences of fetal demise. These data support the notion that high dose vardenafil may be safe and effective at reducing blood pressure during a virus-associated hypertensive pregnancy.


Sign in / Sign up

Export Citation Format

Share Document